---
title: "ALPMY.US (ALPMY.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ALPMY.US/news.md"
symbol: "ALPMY.US"
name: "ALPMY.US"
parent: "https://longbridge.com/en/quote/ALPMY.US.md"
datetime: "2026-05-20T07:42:00.431Z"
locales:
  - [en](https://longbridge.com/en/quote/ALPMY.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ALPMY.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ALPMY.US/news.md)
---

# ALPMY.US (ALPMY.US) — Related News

### [Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 | PFE Stock News](https://longbridge.com/en/news/286767626.md)
*2026-05-18T04:00:00.000Z*
> Astellas Pharma Inc. will present new oncology data at the 2026 ASCO Annual Meeting, highlighting long-term outcomes and

### [SMC backs first-line metastatic bladder cancer combination after trial results](https://longbridge.com/en/news/286065296.md)
*2026-05-12T08:59:43.000Z*
> The Scottish Medicines Consortium has recommended the reimbursement of enfortumab vedotin with pembrolizumab for adults 

### [NEJM: The new drug setidegrasib directly degrades the KRAS G12D protein, bringing early hope for lung cancer and pancreatic cancer](https://longbridge.com/en/news/285786940.md)
*2026-05-09T01:00:29.000Z*
> The NEJM reported that the novel drug setidegrasib shows early activity in lung cancer and pancreatic cancer patients wi

### [Astellas Pharma Inc. (TSE:4503) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?](https://longbridge.com/en/news/284702726.md)
*2026-04-30T05:55:32.000Z*
> Astellas Pharma Inc. (TSE:4503) reported yearly earnings, with shares dropping 7.8% to JP¥2,306. Revenues met forecasts 

### [Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy](https://longbridge.com/en/news/283482479.md)
*2026-04-21T09:35:56.000Z*
> Pfizer and Astellas have received FDA priority review for their Padcev combination therapy for muscle-invasive bladder c

### [Merck, Pfizer, Astellas Drug Combo Gets Speedy FDA Review in Bladder Cancer](https://longbridge.com/en/news/283347501.md)
*2026-04-20T11:52:01.000Z*
> Merck, Pfizer, and Astellas Pharma have received priority review from the FDA for their Keytruda/Padcev drug combination

### [Astellas Pharma (ALPMY) Projected to Post Earnings on Friday](https://longbridge.com/en/news/283092919.md)
*2026-04-17T05:11:43.000Z*
> Astellas Pharma (OTCMKTS:ALPMY) is set to release its earnings on April 24, with analysts expecting earnings of $0.1775